Download (534Kb) - Repozitorij Medicinskog fakulteta Sveučilišta u ...

11. Morgensztern D, Lossos IS. Molecular prognostic factors in diffuse large B-cell lymphoma. Curr TreatOptions Oncol 2005;6:269-77.12. Gandhi MK, Marcus RE. Follicular lymphoma: time for a re-think? Blood Rev 2005;19:165-78.13. Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assessclinical aggressiveness and guide the choice of treatment. Blood 2005;105:301-7.14. Harris NL, Jaffe ES, Stein H, et al. A Revised European-American Classification of LymphoidNeoplasms: A Proposal From the International Lymphoma Study Group. Blood 1994;84:1361-92.15. Pileri SA, Dirnhofer S, Went PH, et al. Diffuse large B-cell lymphoma: one or more entities? Presentcontroversies and possible tools for its subclassification. Review. Histopathology 2002;41:482-509.16. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation.Nat Rev Immunol 2002;2:920-32.17. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6351-7.18. Engelhard M, Brittinger G, Huhn D, et al. Subclassification of diffuse large B-cell lymphomasaccording to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is asignificant prognostic risk factor. Blood 1997;89:2291-7.19. Baars JW, de Jong D, Willemse EM, et al. Diffuse large B-cell non Hodgkin lymphomas: the clinicalrelevance of histological subclassification. Br J Cancer 1999;79:1770-6.20. Maes B, Anastasopoulos A, Kluin – Nelemans JC, et al. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.Ann Oncol 2001;12:835-8.21. Xu Y, Kroft SH, McKenna RW, Aquino DB. Prognostic significance of tumour-infiltrating Tlymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flowcytometry study. Br J Haematol 2001;112:945-9.